Biogen (BIIB) Competitors $149.89 -0.19 (-0.13%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$149.04 -0.84 (-0.56%) As of 10/24/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. AMGN, GILD, IONS, MRNA, PRTA, SAVA, VRTX, BMY, LLY, and PFEShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), Eli Lilly and Company (LLY), and Pfizer (PFE). These companies are all part of the "medical" sector. Biogen vs. Its Competitors Amgen Gilead Sciences Ionis Pharmaceuticals Moderna Prothena Cassava Sciences Vertex Pharmaceuticals Bristol Myers Squibb Eli Lilly and Company Pfizer Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Do analysts recommend BIIB or AMGN? Biogen currently has a consensus target price of $180.69, indicating a potential upside of 20.55%. Amgen has a consensus target price of $300.94, indicating a potential upside of 3.15%. Given Biogen's stronger consensus rating and higher probable upside, research analysts plainly believe Biogen is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.35Amgen 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.28 Is BIIB or AMGN more profitable? Amgen has a net margin of 18.96% compared to Biogen's net margin of 15.31%. Amgen's return on equity of 174.71% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Amgen 18.96%174.71%13.12% Do insiders and institutionals have more ownership in BIIB or AMGN? 87.9% of Biogen shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, BIIB or AMGN? Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.27$1.63B$10.4614.33Amgen$33.42B4.70$4.09B$12.2323.86 Does the media favor BIIB or AMGN? In the previous week, Biogen had 7 more articles in the media than Amgen. MarketBeat recorded 45 mentions for Biogen and 38 mentions for Amgen. Amgen's average media sentiment score of 1.45 beat Biogen's score of 1.02 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 21 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 32 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, BIIB or AMGN? Biogen has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. SummaryAmgen beats Biogen on 11 of the 16 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.98B$3.46B$6.21B$10.81BDividend YieldN/A2.28%5.72%4.80%P/E Ratio14.3328.5131.6030.98Price / Sales2.27497.40595.06133.64Price / Cash6.4946.9537.2561.86Price / Book1.3110.4012.056.61Net Income$1.63B-$52.83M$3.34B$277.10M7 Day Performance4.82%2.10%1.94%2.57%1 Month Performance9.11%10.17%6.88%3.20%1 Year Performance-17.50%16.57%56.06%33.22% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.7242 of 5 stars$149.89-0.1%$180.69+20.5%-17.5%$21.98B$9.68B14.337,605Trending NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionAMGNAmgen4.5795 of 5 stars$301.79+1.0%$305.50+1.2%-8.0%$162.71B$33.42B24.7128,000Positive NewsAnalyst ForecastGILDGilead Sciences4.93 of 5 stars$122.800.0%$120.04-2.2%+35.9%$152.27B$28.75B24.4517,600Positive NewsUpcoming EarningsAnalyst ForecastIONSIonis Pharmaceuticals3.3029 of 5 stars$73.23+0.2%$78.50+7.2%+80.8%$11.69B$705M-39.851,069Upcoming EarningsAnalyst ForecastMRNAModerna4.1771 of 5 stars$27.39+5.3%$39.93+45.8%-49.6%$10.71B$3.24B-3.645,800Trending NewsAnalyst ForecastAnalyst RevisionPRTAProthena2.5264 of 5 stars$10.45+5.4%$20.50+96.1%-35.8%$560.42M$135.16M-1.85130Positive NewsSAVACassava Sciences2.4 of 5 stars$4.41+2.4%$2.00-54.6%-85.8%$213.29MN/A-1.7330Options VolumeVRTXVertex Pharmaceuticals4.8993 of 5 stars$418.29+0.4%$494.38+18.2%-11.8%$107.27B$11.02B29.916,100Positive NewsAnalyst ForecastBMYBristol Myers Squibb4.9643 of 5 stars$43.66+0.1%$57.23+31.1%-15.5%$88.90B$48.30B17.6134,100Trending NewsUpcoming EarningsAnalyst RevisionLLYEli Lilly and Company4.9143 of 5 stars$805.12+0.3%$938.61+16.6%-7.5%$761.91B$45.04B52.6247,000Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionPFEPfizer4.9614 of 5 stars$24.62+0.4%$28.13+14.3%-12.9%$140.01B$63.63B13.1081,000Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Amgen Competitors Gilead Sciences Competitors Ionis Pharmaceuticals Competitors Moderna Competitors Prothena Competitors Cassava Sciences Competitors Vertex Pharmaceuticals Competitors Bristol Myers Squibb Competitors Eli Lilly and Company Competitors Pfizer Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
